BOLT
NASDAQ · Biotechnology
Bolt Biotherapeutics Inc
$5.77
+0.37 (+6.85%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.48M | 3.98M | 4.32M |
| Net Income | 321.1K | 267.7K | 303.4K |
| EPS | — | — | — |
| Profit Margin | 7.2% | 6.7% | 7.0% |
| Rev Growth | +17.1% | +11.2% | +18.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.37M | 2.96M | 2.24M |
| Total Equity | 8.38M | 7.70M | 8.12M |
| D/E Ratio | 0.28 | 0.39 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 558.0K | 477.9K | 559.3K |
| Free Cash Flow | 314.3K | 225.1K | 222.9K |